August 17, 2026

The Infusion Providers Alliance (IPA) submitted comments to the Senate Finance Committee in response to the Request for Information, “Commonsense Policy Options to Lower Drug Prices for Patients,” released by Senate Finance Committee Ranking Member Ron Wyden and other Senate Democrats.

IPA’s comments emphasized the importance of preserving patient access to community-based infusion providers, which offer lower-cost, more convenient access to complex biologic therapies and can achieve clinical outcomes comparable to or better than other sites of service for appropriate patients.

As the Committee considers policy options and future legislation, preserving patient access to community-based settings and providers’ ability to safely deliver complex therapies should be a principal consideration. Policies that inadvertently weaken community-based infusion providers risk accelerating provider consolidation and shifting care to higher-cost hospital settings, ultimately increasing costs for both Medicare and patients.

IPA’s feedback to the RFI focused on three specific issues:

  • Medicare Part B payment reform and price-linked compensation. IPA urged Congress to enact H.R. 4299, the Protecting Patient Access to Cancer and Complex Therapies Act, to address the looming provider reimbursement and patient access consequences of negotiated Part B drug prices while preserving the Medicare savings and beneficiary affordability associated with the Medicare Drug Price Negotiation Program. IPA also expressed willingness to work with Congress on longer-term reforms to Part B add-on payments linked to drug prices, provided that any potential reforms preserve the aggregate resources needed to safely deliver complex therapies today and in the future. IPA emphasized that any such reforms must account for the resource intensity, complexity, and costs associated with drug administration, be developed over a sufficient time period and with sufficient stakeholder input, treat stakeholders equitably, and safeguard patient access.
  • Policy ideas to help boost the biosimilar market and address “underwater biosimilar” dynamics. IPA highlighted market dynamics that can cause certain provider-administered biosimilars to be reimbursed below providers’ acquisition costs, creating barriers to patient access and discouraging use of clinically appropriate lower-cost alternatives. IPA recommended policy changes to support sustainable reimbursement and encourage greater biosimilar adoption.
  • Vertical integration and white bagging practices. IPA raised concerns with insurer and PBM practices arising from vertical integration, particularly insurer-mandated specialty pharmacy sourcing, or “white bagging,” of provider-administered drugs. IPA also highlighted self-administration mandates that can interfere with treatment decisions made by patients and their physicians, increase administrative burdens, and limit patient and provider choice.

Read IPA’s full comments in response to the Senate Finance Committee’s Request for Information.

About the Infusion Providers Alliance

The Infusion Providers Alliance (IPA) is committed to protecting the integrity of the provider-patient relationship by empowering providers and patients to choose the most appropriate treatment together. We advocate for policies that ensure timely and adequate patient access to high quality care in IPA members’ convenient, community-based, non-hospital settings. IPA members operate over 1,000 in-office or stand-alone ambulatory infusion centers across 45 states nationwide, delivering value to the health care system and improved outcomes to patients.

All inquiries should be emailed to ewarren@infusionprovidersalliance.org.